Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

from Oncology Learning Network · host HMP Global

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell lymphoma, supporting this regimen as a potential new frontline standard of care regardless of molecular subtype.

Episode metadata supplied by the publisher feed · Published Jul 8, 2026

Embed this episode

Attribution link and audio player

Ready to play

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

0:00 6:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 6 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on July 8, 2026.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!